XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 33.23

+0.9%

Nov 19 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. Louis Ricca who wrote (5171)	12/21/1997 11:44:00 AM
From: aknahow	Read Replies (1) of 17367

Dr. Ricca, good to hear from you. Approval may or may not come this year but we should by June know more about the trial for meningococcemia. Think many are satisified with the cos scientific progress but of course are disapointed the stock did not just go way up. Having participated with IDEC by providing a patent, XOMA is now receiving royalties on a product that should have peak sales of $400 million. First years sales may be $175 to $200 million. We don't know what percent XOMA receives but even at 2% it will be a positive factor as we wait. The trauma II trials also led to IMO a more specific endpoint for the phase III trials, and this also seems bettethan something more nebulous. Xoma will also be presenting along with Merk in a conference on antibiotic resistance mentioned by Bob K in one of his post.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next